➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Boehringer Ingelheim
Express Scripts
Harvard Business School
Mallinckrodt

Last Updated: June 19, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Thymalfasin


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Thymalfasin?

Thymalfasin is an investigational drug.

There have been 19 clinical trials for Thymalfasin. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2015.

The most common disease conditions in clinical trials are Lung Neoplasms, Infection, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are SciClone Pharmaceuticals, Zhejiang Provincial People’s Hospital, and Sun Yat-sen University.

There is one US patent protecting this investigational drug and seventeen international patents.

Recent Clinical Trials for Thymalfasin
TitleSponsorPhase
Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 InfectionRhode Island HospitalPhase 2
Thymosin Alpha 1 to Prevent COVID-19 Infection in Elderly Renal Dialysis PatientsDavita Clinical ResearchEarly Phase 1
Thymosin Alpha 1 to Prevent COVID-19 Infection in Elderly Renal Dialysis PatientsNephrology Associates of Northern Virginia, Inc.Early Phase 1

See all Thymalfasin clinical trials

Clinical Trial Summary for Thymalfasin

Top disease conditions for Thymalfasin
Top clinical trial sponsors for Thymalfasin

See all Thymalfasin clinical trials

US Patents for Thymalfasin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Thymalfasin   Get Started Free Derivatives of uridine 5'-cyclophosphate useful to treat hepatitis C viral infections Ligand Pharmaceuticals Incorporated (La Jolla, CA)   Get Started Free
Thymalfasin   Get Started Free Method of diagnosing and treating cancer using B-catenin splice variants The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC)   Get Started Free
Thymalfasin   Get Started Free Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC)   Get Started Free
Thymalfasin   Get Started Free Use of inhibitors of Bruton'S tyrosine kinase (Btk) Pharmacyclics LLC (Sunnyvale, CA)   Get Started Free
Thymalfasin   Get Started Free Use of inhibitors of Bruton's tyrosine kinase (Btk) Pharmacyclics LLC (Sunnyvale, CA)   Get Started Free
Thymalfasin   Get Started Free Inhibition of hypoxia-inducible factor activity with carica papaya extracts The Regents of the University of California (Oakland, CA) Universiti Putra Malaysia (Selangor Darul Ehsan, MY)   Get Started Free
Thymalfasin   Get Started Free Substituted indole Mcl-1 inhibitors Vanderbilt University (Nashville, TN)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Thymalfasin

Drugname Country Document Number Estimated Expiration Related US Patent
Thymalfasin World Intellectual Property Organization (WIPO) WO2015077368 2033-11-22   Get Started Free
Thymalfasin Australia AU2006213610 2025-02-10   Get Started Free
Thymalfasin Canada CA2596845 2025-02-10   Get Started Free
Thymalfasin Denmark DK1851340 2025-02-10   Get Started Free
Thymalfasin European Patent Office EP1851340 2025-02-10   Get Started Free
Thymalfasin Hong Kong HK1115165 2025-02-10   Get Started Free
Thymalfasin Japan JP2008535474 2025-02-10   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Moodys
AstraZeneca
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.